New N-phenylpyrrolamide inhibitors of DNA gyrase with improved antibacterial activity

Cotman, Andrej Emanuel (avtor), Fulgheri, Federica (avtor), Piga, Martina (avtor), Peršolja, Peter (avtor), Benedetto Tiz, Davide (avtor), Skok, Žiga (avtor), Durcik, Martina (avtor), Sterle, Maša (avtor), Dernovšek, Jaka (avtor), Zega, Anamarija (avtor), Peterlin-Mašič, Lucija (avtor), Ilaš, Janez (avtor), Tomašič, Tihomir (avtor), Kikelj, Danijel (avtor), Zidar, Nace (avtor)

This study presents the discovery of a new series of N-phenylpyrrolamide inhibitors of bacterial DNA gyrase with improved antibacterial activity. The most potent inhibitors had low nanomolar IC$_{50}$ values against Escherichia coli DNA gyrase (IC$_{50}$; 2–20 nM) and E. coli topoisomerase IV (22i, IC$_{50}$ = 143 nM). Importantly, none of the compounds showed activity against human DNA topoisomerase IIα, indicating selectivity for bacterial targets. Among the tested compounds, 22e emerged as the most effective against Gram-positive bacteria with minimum inhibitory concentration (MIC) values of 0.25 μg mL$^−1$ against Staphylococcus aureus ATCC 29213 and MRSA, and 0.125 μg mL$^−1$ against Enterococcus faecalis ATCC 29212. For Gram-negative bacteria, compounds 23b and 23c showed the greatest efficacy with MIC values ranging from 4 to 32 μg mL$^−1$ against E. coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853, Acinetobacter baumannii ATCC 17978 and A. baumannii ATCC 19606. Notably, compound 23b showed promising activity against the clinically relevant Gram-negative pathogen Klebsiella pneumoniae ATCC 10031, with an MIC of 0.0625 μg mL$^−1$. Furthermore, compounds 23a and 23c exhibited significantly lower susceptibility to resistance development compared to novobiocin in S. aureus ATCC 29213 and K. pneumoniae ATCC 10031. Overall, the most promising compounds of this series showed excellent on-target potency, marking a significant improvement over previous N-phenylpyrrolamide inhibitors.

• Jezik: Angleški jezik
• Vrsta gradiva: Članek v reviji
• Tipologija: 1.01 - Izvirni znanstveni članek
• Organizacija: FFA - Fakulteta za farmacijo
• Status publikacije: Objavljeno
• Različica publikacije: Objavljena publikacija
• Leto izida: 2024
• Št. strani: Str. 28423-28454
• Številčenje: Vol. 14
• PID: 20.500.12556/RUL-162177
• UDK: 615.4:54
• ISSN pri članku: 2046-2069
• DOI: 10.1039/d4ra04802d
• COBISS.SI-ID: 206901507
• Datum objave v RUL: 19.09.2024

Gradivo je del revije

• Naslov: RSC advances
• Založnik: RSC Publishing
• ISSN: 2046-2069
• COBISS.SI-ID: 2513252

Licence

• Licenca: CC BY 3.0, Creative Commons Priznanje avtorstva 3.0 Nedoločena
• Povezava: https://creativecommons.org/licenses/by/3.0/deed.sl
• Opis: Dovoljuje kopiranje in razširjanje vsebin v kakršnemkoli mediju in obliki. Dovoljuje remixanje, urejanje, predelava in vključevanje vsebine v lastna dela v vse namene, tudi komercialne. Primerno morate navesti avtorja, povezavo do licence in označiti spremembe, če so kakšne nastale. To lahko storite na kakršenkoli razumen način, vendar ne na način, ki bi namigoval na to, da dajalec licence podpira vas ali vašo uporabo dela. Ne smete uporabiti pravnih določil ali tehničnih ukrepov, ki bi pravno omejili ali onemogočilo druge, da bi storili karkoli, kar licenca dovoli.

Sekundarni jezik

• Jezik: Slovenski jezik
• Ključne besede: N-fenilpirolamidni inhibitorji, bakterijske DNA giraze, sinteza spojin, antibakterijsko delovanje